Arrowhead Pharmaceuticals (ARWR) Earning Somewhat Positive Media Coverage, Study Shows
News coverage about Arrowhead Pharmaceuticals (NASDAQ:ARWR) has trended somewhat positive on Saturday, Accern reports. The research firm rates the sentiment of news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Arrowhead Pharmaceuticals earned a coverage optimism score of 0.17 on Accern’s scale. Accern also gave news headlines about the biotechnology company an impact score of 44.8102481117868 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the media headlines that may have effected Accern’s analysis:
- Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Traded Much Higher Than Its 50 Day Moving Average – First News 24 (firstnewspaper24.com)
- Why this stock is considered to be Overbought? Arrowhead Pharmaceuticals, Inc. (ARWR) RSI is at 70.00 – Voice Of Analysts (analystsbuzz.com)
- What Technical Analysis say About Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)? – The Oracle Examiner (oracleexaminer.com)
- Arrowhead to Present at Chardan Gene Therapy Conference (finance.yahoo.com)
- Arrowhead Pharmaceuticals Inc (NASDAQ:ARWR): Our Subscribers Are Up 40% So Far In Quick Time – Market News Call (marketnewscall.com)
Shares of Arrowhead Pharmaceuticals (NASDAQ ARWR) opened at 4.25 on Friday. Arrowhead Pharmaceuticals has a 12-month low of $1.20 and a 12-month high of $7.28. The firm’s market cap is $317.78 million. The stock’s 50 day moving average is $3.30 and its 200-day moving average is $2.08.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings results on Thursday, August 3rd. The biotechnology company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.06. The business had revenue of $9.34 million for the quarter, compared to the consensus estimate of $5.29 million. Arrowhead Pharmaceuticals had a negative net margin of 201.84% and a negative return on equity of 46.73%. On average, analysts anticipate that Arrowhead Pharmaceuticals will post ($0.42) EPS for the current fiscal year.
A number of analysts recently commented on ARWR shares. ValuEngine upgraded shares of Arrowhead Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, August 24th. Cantor Fitzgerald reiterated a “hold” rating and issued a $2.00 target price (up from $1.00) on shares of Arrowhead Pharmaceuticals in a report on Friday, September 15th. William Blair upgraded shares of Arrowhead Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, September 18th. Piper Jaffray Companies reiterated a “hold” rating and issued a $2.00 target price on shares of Arrowhead Pharmaceuticals in a report on Friday, July 28th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a report on Wednesday, September 13th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. Arrowhead Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $2.00.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Stock Ratings for Arrowhead Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.